Review Article

ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease

Jithin Kuriakose, Augusto C. Montezano and Rhian M. Touyz
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom
Correspondence: Rhian M. Touyz (rhian.touyz@glasgow.ac.uk)

The two axes of the renin–angiotensin system include the classical ACE/Ang II/AT1 axis and the counter-regulatory ACE2/Ang-(1-7)/Mas1 axis. ACE2 is a multifunctional monocarboxypeptidase responsible for generating Ang-(1-7) from Ang II. ACE2 is important in the vascular system where it is found in arterial and venous endothelial cells and arterial smooth muscle cells in many vascular beds. Among the best characterized functions of ACE2 is its role in regulating vascular tone. ACE2 through its effector peptide Ang-(1-7) and receptor Mas1 induces vasodilation and attenuates Ang II-induced vasoconstriction. In endothelial cells activation of the ACE2/Ang-(1-7)/Mas1 axis increases production of the vasodilator’s nitric oxide and prostacyclin’s and in vascular smooth muscle cells it inhibits pro-contractile and pro-inflammatory signaling. Endothelial ACE2 is cleaved by proteases, shed into the circulation and measured as soluble ACE2. Plasma ACE2 activity is increased in cardiovascular disease and may have prognostic significance in disease severity. In addition to its enzymatic function, ACE2 is the receptor for severe acute respiratory syndrome (SARS)-coronavirus (CoV) and SARS-Cov-2, which cause SARS and coronavirus disease-19 (COVID-19) respectively. ACE-2 is thus a double-edged sword: it promotes cardiovascular health while also facilitating the devastations caused by coronaviruses. COVID-19 is associated with cardiovascular disease as a risk factor and as a complication. Mechanisms linking COVID-19 and cardiovascular disease are unclear, but vascular ACE2 may be important. This review focuses on the vascular biology and (patho)physiology of ACE2 in cardiovascular health and disease and briefly discusses the role of vascular ACE2 as a potential mediator of vascular injury in COVID-19.

Introduction

The renin–angiotensin system (RAS) plays a pivotal role in the regulation of blood pressure, electrolyte and water homeostasis, vascular tone and cardiovascular and renal health [1]. It is a peptidergic system comprising a circulating and a tissue component [2]. Activation is initiated with the release of liver-derived angiotensinogen into the circulation, where it is cleaved by kidney-derived renin into angiotensin I (Ang I) [3], which undergoes further cleavage to angiotensin II (Ang II) by angiotensin-converting enzyme (ACE), expressed mainly in pulmonary endothelial cells (Figure 1). In addition to the classical Ang I/ACE/Ang II pathway, an alternate pathway was identified when ACE2, a homologue of ACE, was discovered [4,5]. ACE2 hydrolyses multiple peptides, including Ang I and Ang II to produce Ang-(1-9) and Ang-(1-7) respectively [6].

Ang II is the main effector peptide of the RAS and signals via Ang II type 1 (AT1R) and Ang II type 2 receptors (AT2R) [7]. Ang II binding to the AT1R leads to coupling of G proteins (G_{i}/G_{o}, G_{12}/G_{13} and G_{q}/G_{11}), second messenger signaling through Ca^{2+} and reactive oxygen species (ROS) generation with
Figure 1. Mechanisms involved in the generation and catabolism of angiotensin peptides, including Ang-(1-7)

Renin converts angiotensinogen to angiotensin I, which is cleaved by ACE to generate angiotensin II. ACE2, PCP and PEP catalyze the conversion of angiotensin II to angiotensin-(1-7). Angiotensin-(1-7) can also be formed from angiotensin I by ACE2, which involves the production of the intermediate form angiotensin-(1-9) and its cleavage by ACE, NEP or PEP. Angiotensin II signals through AT1 and AT2 receptor, while angiotensin-(1-7) signals through Mas1 and MrgD. ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2; AT1R, angiotensin II type 1 receptor; AT2R, angiotensin II type 2 receptor; NEP, neutral endopeptidase; Mas1, Mas1 receptor; MrgD, Mas-related-G-protein-coupled receptor D; PCP, prolyl carboxypeptidase; PEP, prolyl oligopeptidase; THOP, thimet oligopeptidase.

Subsequent activation of downstream signaling molecules including myosin light chain kinase (MLCK), calcium channels, phospholipases, Rho kinase, mitogen-activated protein kinases (MAPK), serine threonine kinases (PI3K, Akt, PKC) and tyrosine kinases (c-Src, JAK/STAT, epidermal growth factor receptor (EGFR)) [8]. Ang II binding to the AT2R induces endothelial nitric oxide synthase (eNOS) activation, nitric oxide (NO) generation, protein tyrosine phosphatase activation and sphingolipid signaling leading to vasorelaxation, decreased vascular tone and natriuresis [9]. The major (patho)physiological actions of Ang II, including vasoconstriction, inflammation and fibrosis, are mediated via AT1Rs [10,11]. In general, AT2R-mediated actions oppose those of the AT1R; however, the exact physiological role of AT2Rs in humans still remains unclear.

Whereas ACE cleaves the decapeptide Ang I to the octapeptide Ang II, ACE2 cleaves Ang I and Ang II to form Ang-(1-9) and Ang-(1-7), respectively [4,12]. ACE2 is a negative regulator of the RAS because it decreases Ang II levels and increases Ang-(1-7) and Ang-(1-9), which are vasodepressor peptides that counteract the vasoconstrictor actions of Ang II [13,1]. Beyond Ang I and Ang II, ACE2 has numerous biological substrates including (des-Arg9)-bradykinin, an agonist of the B1 receptor, apelin-13, a vasoconstrictor and other non-RAS peptides including kinetensin, dynorphin A and neurotensin [14]. Ang-(1-7) is also generated from Ang I by thimet oligopeptidase (THOP1), prolyl oligopeptidase (PEP) and neutral endopeptidase (NEP), while carboxypeptidase A and prolyl carboxypeptidase (PCP) generate Ang-(1-7) from Ang II [15–17]. Ang-(1-7) signals mainly through receptor Mas1 and to a lesser extent through Mas related G protein-coupled receptor D (MrgD) [18,19]. Activation of the ACE2/Ang-(1-7)/Mas1 pathway has vasodilatory, anti-proliferative, anti-inflammatory and anti-fibrotic effects and accordingly has been described as the counter-regulatory arm of the RAS, especially in the vascular system where it protects against increased vascular tone and pathological remodelling and inflammation [20]. Accordingly, there
is increasing interest in targeting ACE2/Ang-(1-7)/Mas1 as a vasoprotective strategy in cardiovascular disease. In addition to its function as a master negative regulator of the RAS, ACE2 acts as the functional receptor for severe acute respiratory syndrome (SARS) coronaviruses (SARS-CoV) including SARS-CoV-2, the cause of coronavirus disease-19 (COVID-19) [21–23].

While ACE2 is widely expressed and has multiple functions influencing various (patho)physiological systems, this review focuses primarily on ACE2 in the vascular system and discusses the role of Ang-(1-7) as the primary peptide effector of ACE2. In addition, we briefly discuss the putative role of vascular ACE2 in the cardiovascular sequelae of COVID-19. It should be highlighted that the field of vascular ACE2, SARS-CoV-2 and COVID-19 is still immature, with many gaps in knowledge. Accordingly, here we only provide some introductory comments on vascular ACE2 and COVID-19. Further original research is needed for a comprehensive review on the topic.

ACE2-a primer
ACE2 shares ~42% homology with ACE and similar to ACE is a transmembrane protein with the extracellular domain comprising catalytic function. In humans, ACE2 protein is encoded by the Ace2 gene on the X-chromosome and is located near a quantitative trait locus linked to hypertension [24]. Unlike ACE, ACE2 does not cleave bradykinin, and it is not inhibited by classical ACE inhibitors [4,25]. The membrane-bound ectodomain of ACE2 is cleaved by tumour necrosis factor-alpha-converting enzyme (TACE/ADAM17), resulting in shedding of ACE2 into the circulation [26]. This is the soluble form of ACE2 and can be measured in plasma. The relative amount of soluble ACE2 to membrane-bound ACE2 is very low, and the physiological role of soluble ACE2 still remains unclear, although it may play a role in the degradation of circulating, but not tissue, Ang II to Ang-(1-7) [27]. Plasma ACE2 activity is low in healthy individuals, possibly due to an endogenous inhibitor [28,29]. However, in cardiovascular disease shedding of ACE2 is increased and plasma ACE2 levels and activity may be increased [30,31]. Plasma ACE2 levels are higher in men than women in health and disease [32] and could relate to the fact that Ace2 is an X-linked gene that might reflect sex-specific differences in control of ACE2 expression and activity.

ACE2 is a multifunctional protein. Beyond its catalytic function generating the peptides Ang-(1-9) and Ang-(1-7), it has noncatalytic actions including the regulation of renal amino acid transport, control of intestinal neutral amino acid transport, pancreatic insulin secretion and coronavirus receptor [33]. As the functional receptor of SARS-CoV and SARS-CoV-2, ACE2 plays a critical role in the pathophysiology of SARS and COVID-19 [20–22]. ACE2 may also be a signaling molecule involved in outside-in signalling [34,35]. The cytosolic domain possesses numerous phosphorylation sites and interacts with calmodulin, which may inhibit shedding of the ectodomain [34,35]. ACE2 has a widespread distribution, and its biological functions likely relate to its expression pattern and activation state in different tissues and organs.

Expression of ACE2 in the vascular system
ACE2 is ubiquitously expressed in human tissues in normal and pathological conditions. In the vascular system, ACE2 is localized in arterial and venous endothelial cells and arterial smooth muscle cells in many organs (Table 1) [12,36–45]. ACE2 protein has also been detected in human atherosclerotic arteries and vascular macrophages [36]. In patients with ischemic heart disease undergoing coronary artery bypass surgery, immunohistochemical analysis showed abundant ACE2 positive cells in diseased vessels, particularly in the neo-intima and media, and in newly formed angiogenic vessels and vasa vasorum, indicating a potential role for ACE2 in pathological conditions [38]. In the human heart, single nuclei RNA sequencing demonstrated cell type-specific expression of ACE2, which was identified in cardiomyocytes, fibroblasts, endothelial cells, smooth muscle cells and pericytes [46]. In patients with heart disease, expression of ACE2 was increased in cardiomyocytes and endothelial cells, whereas fibroblast ACE2 expression was reduced compared with healthy controls [46]. Cardiomyocyte ACE2 content is also increased in patients with aortic stenosis and heart failure [47].

Disruption of ACE/ACE2 balance in the cardiovascular system has been implicated in hypertension [28]. However, ACE2 as a potential therapeutic target in hypertension has been disappointing because ACE2 inhibitors do not increase blood pressure significantly in experimental models and agents that enhance ACE2 activity, including recombinant human ACE2 (rhACE2), have failed to consistently reduce blood pressure in hypertensive models and humans [28,48].

Regulation of vascular ACE2
Mechanisms that control ACE2 in the cardiovascular system are complex and multifactorial. ACE is regulated at the transcriptional and post-transcriptional levels. Molecular elements such as miRNAs (miR-421) [49], transcription
Clinical Science (2021) 135 387–407
https://doi.org/10.1042/CS20200480

Table 1 Table listing the studies which have reported the expression of ACE2 and Mas1 in endothelial cells of different vascular beds

| Vascular bed                  | ACE2/Mas1 expression (Protein/mRNA/Activity) | Species          | References |
|-------------------------------|---------------------------------------------|------------------|------------|
| Carotid artery                | ACE2 mRNA                                   | Human            | [36]       |
| Colon and Brain               | ACE2 protein                                | Human            | [37]       |
| Liver and Spleen              | ACE2 protein                                | Human            | [37]       |
| Oral mucosa and small intestine | ACE2 protein                              | Human            | [37]       |
| Heart, kidney and Testis      | ACE2 protein                                | Human            | [12]       |
| Heart                         | ACE2 mRNA, protein and activity             | Rat              | [38]       |
| Heart                         | ACE2 protein and mRNA                       | Human            | [38]       |
| Pancreas                      | ACE2 protein                                | Human            | [39]       |
| Thyroid and parathyroid gland | ACE2 protein                                | Human            | [39]       |
| Adrenal gland and fallopian tube | ACE2 protein                              | Human            | [39]       |
| Umbilical cord                | ACE2 protein and mRNA                       | Human            | [40]       |
| Lungs                         | ACE2 protein                                | Rat              | [41]       |
| Vasa Vasorum                  | ACE2 protein                                | Human            | [42]       |
| Eye                           | Mas1 protein and mRNA                       | Mouse            | [43]       |
| Lungs                         | Mas1 mRNA and protein                       | Human            | [44]       |
| Brain                         | Mas1 mRNA                                   | Rat              | [45]       |

Abbreviations: ACE-2, angiotensin-converting enzyme 2; Mas1, Mas1 receptor; mRNA, messenger RNA

Factors (C/EBPβ) [50] and signalling molecules (sirtuin-1) [51] have been shown to influence ACE2 expression. ACE2 is also regulated by Ang II through AT1 and AT2 receptors. Increased Ang II/AT1R signaling through ERK1/2 and p38MAPK in cardiovascular and kidney tissue down-regulates ACE2 while expression of ACE is increased [52]. On the other hand, activation of AT2R increases expression and activity of ACE2 in endothelial cells [53].

Aldosterone, through mineralocorticoid receptor activation, may also regulate ACE2 [54]. Aldosterone does not seem to influence ACE2 enzymatic activity but influences its expression. In neonatal cardiomyocytes, aldosterone, but not Ang II, decreased mRNA expression of ACE2, with an associated increase in ACE expression [55]. This imbalance between ACE2 and ACE may contribute to pathological cardiovascular remodelling. These in vitro findings were recapitulated in in vivo studies where aldosterone infusion in rats induced a significant decrease in renal ACE2 expression, particularly in the brush border membrane of the proximal convoluted tubules [56]. This was mediated through mineralocorticoid receptor signalling via proinflammatory NFkB pathways. Spironolactone treatment normalised ACE2 expression in aldosterone-treated rats, supporting the role of mineralocorticoid receptors in aldosterone-mediated ACE2 regulation [56].

Besides humoral mediators, vascular ACE2 is regulated by mechanical factors such as shear stress and stretch. In vascular smooth muscle cells, stretch increased the promoter activity of ACE2 but did not affect its mRNA stability, indicating that mechanical stretch influences ACE2 primarily at the transcriptional level [57]. Molecular processes underlying this involve activator protein-1 (AP-1), which directly interacts with ACE2. NF-κB seems to be a negative regulator of ACE2 in an indirect manner, since the ACE2 promoter site lacks a binding site for NF-κB. PKCβII and JNK1/2 have also been implicated in stretch-mediated ACE2 expression. It has been proposed that physiological stretch up-regulates vascular smooth muscle cell ACE2, which inhibits proliferation and migration, likely through increased Ang-(1-7)/Mas1 signalling [57].

Vascular ACE2 regulation and inhibitors of the RAS

Based on the premise that inhibition of the ACE/Ang II/AT1R pathway potentiates ACE2 actions and activation of the counter-regulatory system, it has been suggested that drugs that inhibit the RAS will influence ACE2 expression and activity [58–60]. Clinical studies demonstrated increased expression of ACE2 in cardiomyocytes and vascular cells in hearts from patients who were treated with ACE inhibitors (ACEi) compared with those treated with angiotensin receptor blockers (ARB) [59]. Moreover, the ACE:ACE2 ratio was four-fold higher in ACEi-treated patients versus healthy individuals and may represent an imbalance between the injurious and protective arms of the RAS. In ACEi-treated patients with coronary artery disease, Ang-(1-7) production was not altered, indicating lack of ACE2 modulation [59,60]. Similarly, in cross-sectional studies involving patients with heart failure, aortic stenosis, coronary artery disease and atrial fibrillation, the use of ACEi or ARBs did not affect plasma ACE2 activity in comparison...
with untreated patients [61–63]. In contrast, other studies in patients with hypertension showed that olmesartan, but not losartan, candesartan, valsartan or telmisartan, increased urinary ACE2, indicating a possible drug-specific effect [64].

In rodent models of cardiovascular injury, ACEi and ARBs have been associated with both up-regulation and down-regulation of circulating and cardiovascular ACE2 [65–69]. Early studies in rodents showed that ACEi and ARBs enhance tissue ACE2 expression and increase plasma Ang-(1-7) levels. Studies in experimental models of hypertension, coronary artery ligation, atherosclerosis and diabetes, reported that ACEi and ARB treatment increases ACE2 gene expression, plasma ACE2 levels and ACE2 activity [70]. Based on these findings, it was suggested that beneficial clinical effects of ACEi and ARBs may relate, at least in part, to inhibition of the ACE/Ang II pathway and activation of the ACE2/Ang-(1-7) pathway [69,70]. Supporting this, experimental studies showed that the Mas1 receptor antagonist (A779) blocked ACE2/Ang-(1-7) responses of ACEi and ARBs [71]. While there is strong evidence that inhibitors of the RAS increase ACE2 expression at the gene level in vessels, heart and kidneys, this has not been consistently demonstrated at the protein level. The functional significance of this is unclear and reflects the complexity of the ACE2 system.

In addition to ACEis and ARBs, mineralocorticoid receptor antagonists have been shown to influence ACE2 expression. Spironolactone and eplerenone increase levels of ACE2 in plasma samples from patients with heart failure as well as in heart tissue from experimental models of cardiovascular disease [72]. These findings suggest that beneficial effects of mineralocorticoid receptor antagonists may be mediated, at least in part, by up-regulating ACE2 and the vasoprotective arm of the RAS.

**Functions of vascular ACE2**

The exact physiological function of vascular ACE2 is still unclear, but it may be an important regulator of normal endothelial and vascular smooth muscle cell function by fine-tuning and modulating vasoinjurious effects of Ang II (Figure 2). In pathological conditions, vascular ACE2 may play a role in preventing pathological vascular remodelling. In cultured human endothelial cells, activation of endogenous ACE2 inhibits Ang II-induced phosphorylation of ERK1/2 and c-Src, reduces Nox-derived ROS generation and increases phosphorylation of eNOS and production of NO [80].

---

**Figure 2.** Schematic depicting the opposing effects of ACE/AngII/AT1R axis and ACE2/Ang-(1-7)/Mas1 axis in the vasculature

Increased signalling through the ACE/AngII/AT1R axis promotes vascular injury while signalling through the ACE2/Ang-(1-7)/Mas1 axis leads to vasoprotection from the injury caused by ACE/AngII/AT1R axis stimulation. ACE, angiotensin-converting enzyme; ACE2, angiotensin converting enzyme two; Ang II, angiotensin two; Ang-(1-7), angiotensin 1 to 7; AT1R, angiotensin two type one receptor; Mas1, mas1 receptor.
of NO, processes that promote vasorelaxation [73,74]. Deletion of vascular smooth muscle cell ACE2 leads to phenotypic switching to a proliferative and pro-inflammatory state [75], processes that are reversed or prevented in cells in which ACE2 is up-regulated [76]. In human vascular smooth muscle cells, ACE2-derived Ang-(1-7) attenuates Ang II-mediated proliferation and inhibits vascular calcification and atherosclerosis [76,77].

ACE2 has also been shown to influence the function of endothelial progenitor cell-derived exosomes, especially related to phenotypic de-differentiation of vascular smooth muscle cells. In co-culture experiments with vascular smooth muscle cells, exosomes released from ACE2-expressing endothelial progenitor cells reduced proliferation, migration and pro-inflammatory effects of Ang II [78]. These ACE2-dependent processes attenuated synthetic phenotypic switching through molecular events that downregulate NF-kB, thereby maintaining vascular smooth muscle cell function in its normal state [78].

ACE2 and vascular pathophysiology in experimental models

Transgenic models have revealed the importance of vascular ACE2 in (patho)physiological conditions. One of the most important studies interrogating the specific role of vascular ACE2 in intact systems was that of Rentzsch and colleagues [79], where human ACE2 was expressed in a vascular smooth muscle cell-specific manner in spontaneously hypertensive stroke prone rats (SHRSP). In these transgenic hypertensive rats, amplification of vascular smooth muscle cell ACE2 was associated with significantly reduced blood pressure, decreased vasoconstrictor responses to Ang II and normalization of endothelium-dependent vasorelaxation, effects that were blocked by treatment with an ACE2 inhibitor [80]. Similar observations were made in lentiviral overexpression of ACE2 in spontaneously hypertensive rats (SHR) [80]. In SHR treated with the ACE2 activator xanthone, development of hypertension was attenuated, and vascular remodelling was prevented [81]. SHR and Ang II-infused rats treated with rhACE2 had reduced blood pressure, decreased cardiovascular and renal oxidative stress, and suppressed pathological cardiac remodelling [82]. Together these findings suggest that in hypertension increased vascular ACE2 activity reduces blood pressure likely through a combination of increased degradation of Ang II and augmented Ang-(1-7) production, which improve vascular function. In Ang II-induced hypertension in mice, pretreatment with rhACE2 decreased blood pressure through processes that enhanced Ang II degradation rather than by increasing Ang-(1-7) levels [27]. Supporting these findings, genetic ablation of systemic ACE2 in C57BL/6 mice resulted in reduced NO bioavailability, increased oxidative stress and vascular dysfunction leading to significant elevation in blood pressure [83].

Vascular ACE2 may be particularly important in cardiovascular disorders associated with inflammation, fibrosis and remodelling. In atherosclerosis-prone ApoE knockout mice, genetic deletion of ACE2 accelerates vascular inflammation and plaque accumulation [84]. In rabbit aortic segments, ACE2 overexpression inhibited development of early atherosclerotic lesions by suppressing the proliferation and migration of vascular smooth muscle cells and by improving endothelial function [85]. These studies indicated that the anti-atherosclerotic actions of ACE2 may result from reduced Ang II levels, increased Ang-(1-7) production, decreased ACE activity and down-regulation of AT1R signalling [84,85].

A vasoprotective role of ACE2 has also been demonstrated in pulmonary hypertension. In monocrotaline (MCT)-induced pulmonary hypertension in rats, oral administration of ACE2 bioencapsulated in plant cells attenuated the development and progression of pulmonary hypertension and prevented pulmonary vascular remodelling [86]. Chronic treatment with a synthetic ACE2 activator 1-[2-((dimethylamino)ethyl)amino]-4-(hidroximetil)-7-[(4-metilfenil)sulfonil]oxi]-9H-xantona-9 (XNT) attenuated MCT-induced pulmonary hypertension in rats with associated reduction in vascular wall thickness [87]. Pharmacological blockade of Mas1 receptor eliminated the cardioprotective effects of XNT, indicating that XNT elicits its protective effects primarily through the Ang-(1-7)/Mas1 pathway.

ACE2 and vascular disease in humans

ACE2 mRNA and protein have been demonstrated in human atherosclerotic vessels, aortic aneurysms and coronary arteries in patients with heart failure [88–90]. ACE2 is expressed in both early and advanced atherosclerotic lesions [36]. While the content of ACE2 does not change during atherogenesis, ACE2 activity is lower in advanced plaques versus early atherosclerotic lesions. These findings suggest that ACE2 regulation changes during atherogenesis and that the vasoprotective function of ACE2 may be blunted with disease progression.

Vascular ACE2 has been identified in pathological vascular remodelling. In patients with bicuspid aortic valve, the ascending aorta is dilated, and this is associated with increased expression and activity of ACE2, findings that were
recapitulated in murine models [88]. In this context, ACE2 up-regulation was considered as a compensatory mechanism. In human abdominal aortic aneurysms, ACE2 was identified in the intima, media and adventitial inflammatory cells [89]. Supporting these human findings, ACE2 deficiency in murine models promoted Ang II-induced development of aneurysms, effects that were prevented when ACE2 activity was increased pharmacologically with diminazine aceturate (DIZE) [89]. Hence therapeutic stimulation of ACE2 may protect against vascular remodelling in aortic disease and may have benefit in patients with aortic aneurysms.

Endothelial ACE2 shedding, plasma soluble ACE2 and clinical implications

Shedding of ACE2 from endothelial cells by proteases releases the catalytically active ectodomain into the blood as soluble ACE2, which can be measured in plasma [28,29]. Clinical studies have shown that plasma ACE2 activity is increased in patients with hypertension, diabetes mellitus and chronic kidney disease [28]. However, some clinical studies failed to show increased plasma ACE2 activity in hypertension, while others showed decreased soluble ACE2 activity [28,91]. In pulmonary arterial hypertension plasma ACE2 activity was shown to be reduced [91]. This prompted a clinical study to assess whether human ACE2 therapy would improve pulmonary arterial hypertension. A single infusion of rhACE2 GSK2586881 resulted in significant improvement in cardiac output and pulmonary vascular resistance, suggesting that ACE2 upregulation may be a potential therapeutic strategy [91,92].

ACE2 shedding also occurs in healthy states. Isolated human CD34+ cells from healthy individuals, when exposed to hypoxic conditions, resulted in ACE2 ectodomain shedding [93]. This was further confirmed when blood flow restriction stimulated mobilization of hematopoietic stem/progenitor cells and increased circulating ACE2 levels in healthy subjects [94]. Thus ACE2 shedding may represent a physiological response to stress, which may become dysregulated in pathological conditions.

The functional role of soluble ACE2 is still unclear but may be a biomarker of underlying vascular stress or cardiovascular disease [47]. A recent association study examining the relationship between soluble ACE2 and plasma proteins revealed that plasma ACE2 associates with signaling proteins linked to clathrin-mediated endocytosis, actin cytoskeleton, eukaryotic initiation factor 2 (eIF2), protein ubiquitination and viral exit from host cells [90]. These proteins are involved in cellular endocytosis, exocytosis and intracellular trafficking of signaling molecules and may reflect cell damage and dysfunction in cardiovascular disease [90].

Ang-(1-7)/Mas1 and vascular function

Ang-(1-7) is the major downstream peptide generated from Ang II by ACE2 catalytic activity. The majority of ACE2 vascular effects are mediated by Ang-(1-7) [95]. Ang-(1-7) functions in opposition to Ang II and in the vasculature promotes dilation [1]. Ang-(1-7) is anti-proliferative, anti-fibrotic, anti-inflammatory and anti-angiogenic, thereby maintaining vascular integrity and promoting vascular health [95,96]. These effects are mediated via the G protein coupled receptor Mas1, which signals through multiple pathways, including activation of Akt, increased NO generation, decreased ROS generation, and inhibition of Ang II-stimulated signalling pathways [1,6,73,74,95].

Vasodilation

Vasodilation is the best characterized vascular action of Ang-(1-7) and is evident in large conduit vessels, resistance arteries and microvessels [96,97]. Ang-(1-7) synergistically increases vasodilation induced by bradykinin and ghrelin, and attenuates agonist-induced vasoconstriction [1,98]. While experimental studies clearly support a vasodilatory action of Ang-(1-7), this is less evident in human vessels. Some studies failed to show vasodilation in response to Ang-(1-7) in the forearm circulation of normotensive subjects and patients with hypertension [99,100], while others reported a dose-dependent augmentation of bradykinin vasodilation by Ang-(1-7) in forearm resistance vessels in healthy men, confirming the bradykinin-potentiating effect of Ang-(1-7) identified in experimental models [101]. In the forearm of normotensive patients as well as in mammary arteries in vitro Ang-(1-7) attenuates the vasoconstrictor effect of Ang II, but not noradrenaline [102,103].

Antiproliferative and antifibrotic effects

In vascular smooth muscle cells, Ang-(1-7) opposes the mitogenic actions of Ang II by inhibiting activation of growth signalling pathways such as MAP kinases [104,105]. Ang-(1-7)/Mas1 also inhibits transactivation of growth factor receptors, such as EGFR, resulting in decreased activation of downstream signalling pathways involved in vascular smooth muscle cell proliferation and vascular hypertrophy [106]. In response to vascular injury, Ang-(1-7) reduces
neointimal formation and pathological vascular remodelling [107]. In atherosclerotic prone ApoE knockout mice, Ang-(1-7) and AT1R blockade with losartan improved endothelial function, attenuated macrophage infiltration and inhibited vascular smooth muscle cell proliferation and migration [108]. In addition, Ang-(1-7) prevents vascular calcification and aneurysm formation by inhibiting osteogenic transition of vascular smooth muscle cells [109].

Haematopoietic stem/progenitor cells and vascular repair
In addition to directly influencing vascular function, the ACE2/Ang-(1-7)/Mas1 system activates haematopoietic stem/progenitor cells, important in vascular repair [110–114]. ACE2/Ang-(1-7)/Mas1 activation promotes vasoreparative properties of vascular progenitor cells and reverses reparative dysfunction in pathological conditions [113–118]. In a mouse model of Type 2 diabetes, Ang-(1-7) treatment increased bone marrow and circulating levels of endothelial and mesenchymal stem cells [114]. Similar favourable responses were observed in a rat model of myocardial infarction treated with Ang-(1-7) and in a mouse model of ischaemic stroke where transfusion of lentivirus-ACE2-primed endothelial progenitor cells increased angiogenesis and cerebral microvascular density [115,116]. In vitro studies showed that activation of the ACE2/Ang-(1-7)/Mas1 axis stimulates vascular repair functions of CD34+ cells and enhances the reparative function of dysfunctional endothelial progenitor cells in diabetes [117].

Ang-(1-7) signalling in vascular cells

Endothelial cells, NO and prostacyclin production
Ang-(1-7)-induced NO release by the post-translational regulation of eNOS (phosphorylation at Ser1177 and dephosphorylation at Thr495) is widely accepted as the primary event underlying vasoprotective effects of the peptide [1] (Figure 3). Wortmannin (a phosphatidylinositol 3-kinase (PI3K) inhibitor) blocked Ang-(1-7)-mediated activation of eNOS (Ser1177 phosphorylation) indicating that Ang-(1-7) regulates eNOS via Akt-dependent pathways. Ang-(1-7) also counter-regulates Ang II actions in endothelial cells by reducing Ang II-stimulated activation of c-Src, ERK1/2 and Nox by enhancing SHP-2 phosphorylation [73,74,95]. In human umbilical vein endothelial cells (HUVEC), Ang-(1-7) ameliorated Ang II-induced senescence by increasing the expression of the anti-ageing protein ‘Klotho’ and activation of the antioxidant, nuclear factor-erythroid-2-related factor (Nrf2)/haem-oxygenase 1 pathway [119]. It also blunted Ang II-induced expression of endoplasmic reticulum stress markers (p-eIF2α, ATF-6, CHOP, Grp78, ATF4) and amplified NO production to maintain endothelial cell function [120]. In human cerebral endothelial cells, Ang-(1-7) inhibited Ang II-stimulated ROS production, pro-apoptotic activity and reduced NO levels [121]. Furthermore, protective effects of Ang-(1-7) against other stress inducers, such as thrombin, have been demonstrated in endothelial cells [122].

In addition to regulating production of the vasodilator NO, Ang-(1-7) selectivity increases prostaglandin synthesis [123]. Chronic infusion of Ang-(1-7) in SHR increased urinary excretion of prostaglandin E2 and 6-keto-prostaglandin F1α and induced diuresis, natriuresis, and decreased blood pressure [124]. In endothelial cells, Ang-(1-7) stimulates the production of vasodilator prostacyclins via activation of PLA2 and CaM kinase II/ MAP kinase [123], and in vascular smooth muscle cells prostacyclins play a role in Ang-(1-7) antiproliferative actions [123,125].

Vascular smooth muscle cells and Ang-(1-7) signalling
Ang II is a potent vasoconstrictor that stimulates proliferation, inflammation, fibrosis and migration of vascular smooth muscle cells, processes involved in vascular remodelling in pathological conditions. It is now clear that Ang-(1-7) counteracts these actions by negatively regulating Ang II signaling [125–128]. In vascular smooth muscle cells, Ang-(1-7) opposes Ang II-stimulated pro-oxidative and proliferative signaling, reduces phosphorylation of c-Src, MAPKs and inhibits activation of Nox [105] (Figure 3). Ang-(1-7) attenuates Ang II-induced contraction by inhibiting RhoA/ROCK2 signaling and phosphorylation of moesin and myosin light chain [126]. Other signaling pathways influenced by Ang-(1-7) in vascular smooth muscle cells include NF-κB, IκBα, MAPK, and matrix metalloproteinases [127,128].
Endothelial cell Vascular smooth muscle cell

AT1R
Mas1

Ang II
Ang-(1-7)

Ang-(1-7)

C-Src
ERK1/2
Nox
p22
p47
p40
p67
ROS
SHP2

Senescence

↑ Klotho

Guide肽

↑ Nrf2/HO-1

NOS
NO

PLA2
AA
PGI2
PGE2

↑ Nrf2/HO-1

NFkB
pSer1177

RhoA/ROCK2
pMLC

NFkB

Figure 3. Vascular signalling of Ang-(1-7)/Mas1 in endothelial cells and vascular smooth muscle cells

In endothelial cells, Ang-(1-7) activates eNOS via AKT to produce nitric oxide. Ang-(1-7) also stimulates production of vasodilators such as prostacyclin (PGI2) and prostaglandin (PGE2) via enhancement of phospholipase A2 (PLA2) activity and arachidonic acid (AA) release. Ang-(1-7) via Mas1 counter-regulates Ang II effects by increasing expression of anti-ageing protein klotho which consequently activates Nrf2/HO-1 pathway and activation of c-Src, ERK1/2 and NADPH oxidase (Nox) by enhancing SHP-2 phosphorylation. In smooth muscle cells, Ang-(1-7) via Mas1 receptor opposes Ang II-induced contraction and oxidative stress by attenuating RhoA/ROCK2 signalling, PLC and NADPH activation. Ang-(1-7) also suppresses Ang II-induced proliferation and inflammation by inhibiting MAPKs (ERK1/2, p38MAPK and JNK), MMP-8 and NFκB signalling. AKT, serine threonine specific protein kinase; AngII, angiotensin II; Ang-(1-7), angiotensin-(1-7); AT1R, angiotensin two type one receptor; ERK1/2, extracellular regulated kinase one and two; HO-1, haem oxygenase one; JNK, c-Jun N-terminal kinases; MAPK, mitogen-activated protein kinase; Mas1, mas1 receptor; MMP-8, matrix metalloproteinase 8; NADPH, nicotinamide adenine dinucleotide phosphate; NFκB, nuclear factor kappa B; Nrf2, nuclear factor erythroid 2-related factor 2; PLC, phospholipase C; RhoA/ROCK2, RAAS homolog family member A/Rho associated coiled-coil containing protein kinase 2; ROS, reactive oxygen species; SHP-2, small heterodimer partner 2.

Fibroblasts and Ang-(1-7) signalling

Studies in fibroblasts have also shown protective effects of Ang-(1-7). In renal interstitial fibroblasts, Ang-(1-7) significantly decreased aldosterone-induced pro-fibrotic signaling [129]. In cardiac fibroblasts from Sprague Dawley rats, Ang-(1-7)/Mas1 activated SHP-1, a redox-sensitive protein, and inhibited Ang II-induced phosphorylation of c-Src and its downstream signaling molecules ERK1/2, α-SMA and TGF-β [130]. Metabolomic studies in primary cardiac fibroblasts, demonstrated that Ang-(1-7) blunted Ang II-induced signaling by inhibiting calcium/calmodulin-dependent protein kinase II delta (CaMKIIδ), Nox4, CTGF and ERK1/2 [131].

ACE2/Ang-(1-7) and vascular remodelling

Vascular remodelling is a complex process involving collagen deposition, fibrosis, inflammation, calcification and endothelial dysfunction and occurs with normal ageing and in response to injury and disease. In pathological conditions such as hypertension, atherosclerosis and diabetes mellitus, vascular remodelling is accelerated leading to target organ damage [132]. Studies in ACE2 knockout mice showed augmented vascular stiffness, worsening of vascular injury and potentiation of Ang II effects on oxidative stress, apoptosis and vascular smooth muscle cell phenotypic switching, while ACE2 overexpression inhibited vascular proliferation vascular hypertrophy and improved endothelium-dependent vasorelaxation [75,84,133,134]. Moreover, rhACE2 prevented Ang II-induced vascular remodelling through processes involving JAK-STAT-SOCS signaling [76]. Many of the vasoprotective effects of ACE2 were recapitulated by up-regulation of the Ang-(1-7)/Mas1 system, while pharmacological inhibition or gene deletion of Mas1 prevented ACE2/Ang-(1-7) beneficial effects [135]. In particular, in Mas1−/− mice acetylcholine-induced
vascular relaxation is blunted, and mice exhibit endothelial dysfunction, increased mean arterial blood pressure, cardiac dysfunction, reduced NO production, and increased oxidative stress [135,136]. There is thus convincing pre-clinical evidence that the ACE2/Ang-(1-7)/Mas1 axis negatively regulates Ang II and that it is vasoprotective, highlighting it as a potential therapeutic target in cardiovascular disease, especially in conditions associated with activation of the RAS.

ACE2/Ang-(1-7)/Mas1 and vascular inflammation

Several studies have shown that the ACE2-Ang-(1-7)-Mas1 axis has anti-inflammatory properties in vascular injury [137]. In vitro studies in human aortic smooth muscle cells demonstrated that Ang-(1-7) counteracts inflammatory effects of Ang II by inhibiting iNOS, Nox and pro-inflammatory signaling pathways [138]. In human and rabbit endothelial cells, anti-inflammatory effects of Ang-(1-7) involve lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) [139]. In vivo studies support the anti-inflammatory role of Ang-(1-7). In a mouse model of atherosclerosis, chronic Ang-(1-7) treatment inhibited early atherosclerotic lesion formation by protecting endothelial function and inhibiting the inflammatory response [140].

ACE2/Ang-(1-7)/Mas1, oxidative stress, antioxidants and vascular function

Many of the molecular processes that underlie vascular injury and inflammation in pathological conditions involve Ang II-induced activation of redox-sensitive pathways and oxidative stress [141]. The ACE2/Ang-(1-7)/Mas1 axis counter-regulates oxidative damage in the vascular system by reducing Nox-mediated ROS production and increasing antioxidant capacity [142,143]. In renal arteries from diabetic patients and in conduit and resistance arteries from diabetic mice activation of ACE2/Ang-(1-7) improved endothelial function by decreasing oxidative stress through processes that down-regulate Nox2 and up-regulate antioxidant enzymes [142]. Similar Nox2/ROS actions have been observed in Ang II-stimulated brain microvascular endothelial cells, where Ang-(1-7) opposed pro-apoptotic actions of Ang II by reducing Nox2 expression and decreasing ROS formation [121]. Other Nox isoforms, including Nox2 and Nox4, are also modulated by ACE2/Ang-(1-7) [144]. In a model of ischaemic stroke, Ang-(1-7)-induced neuroprotection was associated with decreased Nox1 expression [145]. In diabetic SHR, Ang-(1-7) treatment improved renal function by inhibiting the Nox4/ROS system [146] and in a mouse model of cardiac hypertrophy AVE 0991, a non-peptide Ang-(1-7) analogue, prevented left ventricular hypertrophy and improved heart function by down-regulating Nox2 and Nox4 and decreasing oxidative stress [147]. In addition, ACE2 overexpression in endothelial progenitor cells decreased Nox4 expression and reduced ROS production [144]. These findings suggest that ACE2 activation may play a role in improving efficacy of endothelial progenitor cell-based therapy in vascular injury by blunting the Nox4/ROS system [144].

ACE2 and Ang-(1-7) further influence the redox state by regulating antioxidant enzymes, including superoxide dismutase (SOD) and Nrf2. Infusion of recombinant human ACE2 (GSK2586881) in patients with pulmonary hypertension was associated with increased plasma levels of SOD2 and reduced oxidative stress [91]. Similarly, in a mouse model of bleomycin-induced pulmonary hypertension, recombinant ACE2 treatment increased pulmonary SOD2 expression, reduced oxidative stress and attenuated development of vascular remodelling [148]. Protective effects of Ang-(1-7) in Ang II-induced cardiac hypertrophy involve Sirt-3 mediated deacetylation of Foxo3a, up-regulation of SOD2 and decreased ROS levels in cardiomyocytes [149]. ACE2/Ang-(1-7) also modulates the transcription factor Nrf2, the master regulator of antioxidant genes. Endothelial cell senescence is attenuated by Ang-(1-7) through pathways that involve Klotho and Nrf2 [119,150]. In models of hyperoxic lung injury, ACE2 activation inhibited inflammation, reduced oxidative stress and activated the Nrf2 antioxidant pathway [150].

Another mechanism whereby ACE2/Ang-(1-7) modulates the oxidative milieu involves a novel nuclear system. In renal cells Ang II-induced ROS production is attenuated by activation of nuclear ACE2/Ang-(1-7) [151]. The functional significance of the nuclear system remains unclear, but it may act as a protective mechanism to prevent accumulation of injurious ROS within the nucleus thereby preventing oxidative DNA damage [151].

Interactions between ACE2/Ang-(1-7)/Mas1 and AT2 receptors

Similar to Mas1, activation of AT2R mediates vasoprotective effects by promoting vasodilation and inhibiting inflammation, fibrosis and apoptosis [152]. Growing evidence indicates that these G protein-coupled receptors interact, especially in the kidney, and that they heterodimerize [153–155]. AT2 and Mas1 receptors co-localize in the renal cortex.
of obese Zucker rats and are independently involved in the production of NO and the regulation of the natriuretic response [154]. In astrocytes, Mas1 and AT2R heterodimerize and are functionally dependent on each other [155]. The biological significance of Mas1:AT2R receptor dimerization remains unclear but interaction between these receptors may amplify signaling and vasoprotective properties.

In addition to physical links between Mas1 and AT2R, cross-talk between these receptors may be mediated by a common ligand, Ang-(1-7). This is supported by studies demonstrating that A779 as well as PD123319 (AT2R antagonist) prevent Ang-(1-7) cellular and vascular actions [153,156]. The inhibitory effects of A779 are well described. In mouse hearts pre-treated with the AT1R blocker losartan, PD123319 prevented Ang-(1-7) induced vasodilation and increased perfusion pressure [153]. Other studies demonstrated that PD123319 inhibits protective effects of Ang-(1-7) in models of endothelial dysfunction [157,158], hepatocellular carcinoma [159], atherosclerosis [160], ischaemic stroke [161], and cerebral autophagy in SHR [162]. However, some studies failed to show a role for AT2R in Ang-(1-7)-mediated effects supporting Mas1 as the primary receptor for the peptide [163,164].

Interactions between ACE2, Ang-(1-7), Mas1 and AT2R have pathophysiological significance. In experimental models of pulmonary hypertension, activation of the ACE2/Ang-(1-7)/Mas1 axis attenuates progression of disease, processes associated with upregulation of AT2R [165]. Further supporting this notion, chronic treatment with compound 21 (AT2R agonist) prevented cardiopulmonary fibrosis and attenuated pulmonary hypertension with an associated increase in mRNA expression of ACE2 and Mas1 indicating that beneficial effects of AT2R activation involve the ACE2-Ang-(1-7)-Mas1 pathway [166]. On the other hand, activation of ACE2/Ang-(1-7) increases expression of AT2R in models of SHR, diabetes, Ang II-induced hypertension and pulmonary hypertension [167-170].

SARS-CoV-2 and COVID-19 implications of vascular ACE2

Beyond its vasoprotective functions, vascular ACE2 may play an important role in cardiovascular disease related to COVID-19, since ACE2 is the receptor through which SARS-CoV-2 enters host cells causing infection [20–23].

ACE2 as the cell entry receptor for SARS-CoV-2

Viral infection studies in various ACE2 expressing cell types across species (human, bats, civet, pigs, mice), computational modelling and cryo-EM experiments demonstrated unambiguously that ACE2 is the receptor for SARS-CoV-2, similar to that for other coronaviruses including SARS-CoV and middle east respiratory syndrome coronavirus (MERS-CoV) [171]. Entry of SARS-CoV-2 into host cells depends on binding with the receptor via the virus surface spike proteins (S-proteins), of which there are 2: the S1-protein possesses a receptor-binding domain (RBD) responsible for viral binding to the host cell and the S2-protein, which contains a fusion peptide domain important for virus:host cell membrane fusion [172]. ACE2, as the cell entry receptor, is probably the key factor determining host cell tropism and infectivity. While ACE2 normally localizes on the plasma membrane with the extracellular N-terminal possessing the catalytic site for generation of Ang-(1-7) (and other peptides), it can undergo proteolytic shedding and post-translational modification by various proteases and enzymes, including transmembrane protease serine 2 (TMPRSS2), disintegrin and metalloproteinase domain-containing protein (ADAM)10, ADAM17 (also called TACE), cathepsins and furin [173,174]. Binding of SARS-CoV-2 via the S-protein to ACE2 prompts cleavage of ACE2 by ADAM17/TACE at the extracellular N-tail, which possesses catalytic activity, producing soluble ACE2 [26], while TMPRSS2 causes proteolytic cleavage of ACE2 at the intracellular C-domain without catalytic activity [23]. TMPRSS2, together with cathepsin B and L, primes ACE2 facilitating membrane fusion and internalization of the S protein:ACE2 complex, essential for host cell infection [23].

Numerous accessory proteins have been identified that may influence viral release, stability and virulence. The 3-terminus of the SARS-CoV-2 genome encodes eight accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b and ORF14) which play important roles in the entry of SARS-CoV-2 [175]. SARS-CoV-2 S-protein 1 has also been shown to bind CD147 a transmembrane glycoprotein of the immunoglobulin superfamily [176], which was previously shown to facilitate SARS-CoV:host cell infection [177]. The complex regulatory processes of SARS-CoV-2:ACE2 interaction have been described in recent publications and the reader is referred to these for further details [21–23].

SARS-CoV-2 and vascular ACE2

Vascular cells express many of the proteases involved in SARS-CoV-2-induced ACE2 post-translational modification, suggesting potential viral infection in the vasculature. ACE2 together with TMPRSS2, ADAM10, ADAM17 and cathepsins have been demonstrated in endothelial cells, although levels of ACE2 and TMPRSS2 are lower than in nasal epithelium [178]. Cardiovascular cells also express CD147 and may play a role in severity of COVID-19 disease in the elderly [178]. Despite increasing evidence that vascular ACE2 is involved in SARS-CoV-2-induced vascular
Vascular ACE2 and the pathophysiology of COVID-19-related cardiovascular disease

While COVID-19 is a viral disease of the respiratory system causing severe and progressive lung damage, it is also associated with significant cardiovascular comorbidities and sequelae [181–183]. In particular, hypertension and diabetes mellitus are major comorbidities of COVID-19, which itself predisposes to thromboembolic disease, acute myocardial injury, myocarditis, heart failure and arrhythmias [182,183]. Patients with COVID-19 who have pre-existing cardiovascular disease have more severe disease and worse outcomes than those without a history of cardiovascular disease [181,182,184,185]. The pathophysiological processes underlying COVID-19-related cardiovascular disease remain unclear, but the vascular RAS system probably plays an important role. In the lungs and other organs, vascular injury and loss of endothelial integrity cause tissue oedema, activation of coagulation pathways, inflammation, endotheliitis and vascular dysfunction, processes contributing to tissue damage and organ failure in COVID-19 [184,186,187].

At the molecular level, vascular ACE2 may be critical (Figure 4). Firstly, SARS-CoV-2 binding to vascular ACE2 may facilitate virus entry into endothelial and vascular smooth muscle cells causing viral infection of the endothelium and vascular media [188]. This probably involves other players as well, such as TMPRSS2 [23]. Post-mortem analysis of different organs in patients with COVID-19 demonstrated endothelial cell viral infection and endotheliitis [188]. Secondly, down-regulation of vascular ACE2 by SARS-CoV-2 may decrease ACE2 activity leading to reduced production of vasoprotective Ang-(1-7) causing endothelial dysfunction and increased vascular permeability [187]. SARS-CoV has been shown to downregulate myocardial ACE2 in patients with severe acute respiratory syndrome [189], and similar process may occur for SARS-CoV-2. Finally, viral infection and down-regulation of the ACE2-Ang-(1-7) pathway could promote increased generation of vascular-derived cytokines and vasoactive factors causing endotheliitis, vascular inflammation and impaired vascular tone [189,190]. Although these processes are plausible and vascular ACE2 might be pivotal in cardiovascular sequelae associated with COVID-19, this awaits confirmation.

Targeting ACE2/Ang-(1-7)/Mas1 and AT2R as potential therapeutic approaches in COVID-19

Considering the importance of ACE2 in cardiovascular (patho)physiology, it has been suggested that the loss of ACE2 catalytic function and dysregulation of the RAS may be responsible for the cardiovascular symptoms reported in COVID-19 patients [181–183,186]. Accordingly, there is growing interest in targeting ACE2, as well as other RAS elements especially Ang-(1-7)/Mas1 and AT2R, as therapeutic strategies in COVID-19 [191]. Studies have suggested (i) ACE2 inhibitors to prevent viral entry, (ii) ACE2 activators to promote Ang-(1-7) anti-inflammatory actions and (iii) soluble human recombinant ACE2 (shrACE2) to saturate and inactivate circulating S-protein, as putative novel therapeutic modalities to prevent SARS-CoV-2 infection of host cells [191–195]. In vitro studies have shown that shrACE2 decreases SARS-CoV-2 infection and clinical trials using shrACE2 (APN01) are currently underway [194,195] (ClinicalTrials.gov identifier NCT04335136). Other clinical trials targeting Ang-(1-7) (ATCO trial) and Mas1 (ClinicalTrials.gov identifier NCT04332666; 04401423; 04375124) are also in progress. In addition, the AT2R agonist VP01 (C21) is being tested as a potential repurposed therapeutic in COVID-19 in the Angiotensin II Type Two Receptor Agonist Covid-19 Trial (ATTRACT) (ClinicalTrials.gov identifier NCT04452435). Outcomes from these clinical trials are awaited.

Conclusions

Vascular function is tightly regulated by the RAS. While the molecular biology, biochemistry and physiology of Ang II are well defined, there is a paucity of information about the vascular ACE2/Ang-(1-7) system, especially in human
Since vascular cells express ACE2, it may be possible that SARS-CoV-2 interaction with vascular ACE2 plays a role in cardiovascular disease associated with COVID-19. SARS-CoV-2 via its spike protein, which is primed by the endogenous transmembrane serine protease 2 (TMPRSS2), binds to ACE2 for cell entry. The virus is endocytosed leading to fusion of viral and cellular membranes and subsequent release of viral RNA into the cytosol which causes viral infection and the down-regulation of endogenous ACE2 and up-regulation of ADAM17. Following the vesicular transport to the cell surface, ADAM17 cleaves the extracellular domain of ACE2 and takes part in processing of different cytokines leading to activation of inflammatory signalling which further down-regulates vascular ACE2. Down-regulation in vascular ACE2 may lead to decreased Ang-(1-7) production contributing to endothelitis, vascular inflammation and impaired vascular tone, which could promote cardiovascular complications in COVID-19. ACE2, angiotensin converting enzyme 2; ADAM17, tumour necrosis factor-alpha-converting enzyme; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

health and disease. It is becoming increasingly apparent that ACE2, through Ang-(1-7)/Mas, is vasoprotective and that down-regulation of ACE2 promotes vascular injury and remodelling, processes that are ameliorated when ACE2 or Ang-(1-7) are up-regulated. Vascular ACE2 is controlled by humoral and mechanical factors and upon ADAM17 activation is shed from endothelial cells into the plasma, where circulating soluble ACE2 might be a predictive marker of vascular health or disease. ACE2 is also regulated by drugs that inhibit the RAS. ACEi and ARBs increase expression of ACE2 and may influence soluble ACE2 activity. Beyond its vasoprotective role in the cardiovascular system, ACE2 is crucially involved in the pathophysiology of COVID-19 as the receptor for SARS-CoV-2. COVID-19 is increasingly being considered as an endothelial and vascular disease. Considering the importance of ACE2 in endothelial and vascular cells, we speculate that vascular ACE2 may play a role in the cardiovascular risk factors and complications of COVID-19. However, this awaits confirmation. Vascular ACE2 is emerging as a major regulatory system potentially involved in many pathologies. It is therefore not surprising that the ACE2/Ang-(1-7)/Mas1 system is gaining enormous interest as a therapeutic target.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.
Funding
This work was supported by grants from the British Heart Foundation [grant numbers FS/18/58/34179 (to J.K.); CH/12/429762, RE/18/6/34217 (to R.M.T.)]; Chief Scientist Office [grant number COV/GLA/20/04]; and the Walton Fellowship, University of Glasgow (to A.C.M.).

Author Contribution
All authors contributed to the writing of this manuscript and approved the final version.

Acknowledgements
Figures were created using images from Servier Medical Art (https://smart.servier.com/) under creative commons licence 3.0.

Abbreviations
α-SMA, alpha-smooth muscle actin; ARB, angiotensin II receptor blocker; ATF-4, activating transcription factor-4; ATF-6, activating transcription factor-6; CHOP, CCAAT-enhancer-binding protein homologous protein; cPLA₂, cyclic phospholipase A₂; c-SRC, SRC proto-oncogene, non-receptor tyrosine kinase; CTGF, connective tissue growth factor; eIF2α, eukaryotic translation initiation factor 2A; ERK, extracellular signal regulated kinase; Grp78, glucose regulated protein, 78kDa; IκBα, I-kappa-B-alpha; JNK, c-Jun N-terminal kinases; NADPH, nicotinamide adenine dinucleotide phosphate; NFκB, nuclear factor kappa B; Nox, NADPH oxidase; Nrf2, nuclear factor erythroid 2-related factor 2; PKCβII, protein kinase C βII; RhoA/ROCK2, RAAS homolog family member A/Rho associated coiled-coil containing protein kinase 2; RNA, ribonucleic acid; Ser, serine; SHP, small heterodimer partner; TGF-β, transforming growth factor beta; Thr, threonine.

References
1 Santos, R., Sampaio, W., Atzamora, A., Motta-Santos, D., Alenina, N. and Bader, M. (2018) The ACE2/Angiotensin-(1-7)/MAS1 axis of the Renin-angiotensin system: Focus on angiotensin-(1-7). Physiol. Rev. 98, 505–553, https://doi.org/10.1152/physrev.00023.2016
2 Bader, M. and Ganten, D (2008) Update on tissue renin-angiotensin systems. J. Mol. Med. 86, 615–621, https://doi.org/10.1007/s00109-008-0336-0
3 Moon, J. (2013) Recent update of Renin-angiotensin-aldosterone system in the pathogenesis of hypertension. Electrolyte. Blood. Press. 11, 41, https://doi.org/10.5049/EBP.2013.11.2.41
4 Tipnis, S., Hooper, N., Hyde, R., Karran, E., Christie, G. and Turner, A. (2000) A human homolog of Angiotensin-converting enzyme. J. Biol. Chem. 275, 33238–33243, https://doi.org/10.1074/jbc.M002615200
5 Turner, A., Tipnis, S., Guy, J., Rice, G. and Hooper, N. (2002) ACEH/ACE2 is a novel mammalian metalloproteinase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can. J. Physiol. Pharmacol. 80, 346–353, https://doi.org/10.1139/y02-021
6 Santos, R.A.S, Oudit, G.Y., Verano-Braga, T., Canta, G., Steckelings, U.M. and Bader, M (2019) The renin-angiotensin system: going beyond the classical paradigms. Am. J. Physiol. Heart Circ. Physiol. 316, 958–970, https://doi.org/10.1152/ajpheart.00723.2018
7 Kaschina, E. and Unger, T, (2003) Angiotensin AT1/AT2 receptors: Regulation, Signalling and Function. Blood Press 12, 70–88, https://doi.org/10.1080/08037050310001057
8 Forrester, S.J., Booz, G.W., Sigmund, C.D., Coffman, T.M., Kawai, T. and Rizzo, V. (2018) Angiotensin II signal transduction: An update on mechanisms of physiology and pathophysiology. Physiol. Rev. 98, 1627–1738, https://doi.org/10.1152/physrev.00038.2017
9 Lemarié, C. and Schiffrin, E. (2009) The angiotensin II type 2 receptor in cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. 11, 19–31, https://doi.org/10.1177/1470320309347785
10 Nguyen, D.C.A. and Touyz, R (2011) A new look at the renin-angiotensin system— Focusing on the vascular system. Peptides 32, 2141–2150, https://doi.org/10.1016/j.peptides.2011.09.010
11 Savoia, C., Burger, D., Nishigaki, N., Montezano, A. and Touyz, R. (2011) Angiotensin II and the vascular phenotype in hypertension. Expert Rev. Mol. Med. 13, e11, https://doi.org/10.1017/S1462399411001815
12 Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Staglino, N. et al. (2000) Novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts Angiotensin I to Angiotensin 1-9. Circ. Res. 87, 5, https://doi.org/10.1161/01.RES.87.5.1
13 Mendoza-Torres, E., Oyarzán, A., Mondaca-Ruff, D., Azocar, A., Castro, P.F., Jalil, J.E. et al. (2015) ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodelling and hypertension. Ther. Adv. Cardiovasc Dis. 9, 217–237, https://doi.org/10.1177/1753944715603972
14 Danilczyk, U. and Penninger, J. (2006) Angiotensin-Converting Enzyme II in the heart and the kidney. Circ. Res. 98, 463–471, https://doi.org/10.1161/01.RES.0000205761.22353.5f
15 Reudelhuber, T. (2006) A place in our hearts for the lowly Angiotensin 1-7 peptide? Hypertension 47, 811–815, https://doi.org/10.1161/HYPERTENSIONAHA.113.01274
16 Santos, R. (2014) Angiotensin-(1-7). Hypertension 63, 1138–1147, https://doi.org/10.1161/HYPERTENSIONAHA.113.01274
17 Pereira, M., Souza, L., Becari, C., Duarte, D., Camacho, F., Oliveira, J. et al. (2013) Angiotensin II-Independent Angiotensin-(1-7) formation in rat hippocampus. Hypertension 62, 879–885, https://doi.org/10.1161/HYPERTENSIONAHA.113.01613
Ishiyama, Y., Gallagher, P., Averill, D., Tallant, E., Brosnihan, K. and Ferrario, C. (2004) Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. *Hypertension* **43**, 970–976, https://doi.org/10.1161/01.HYP.0000124667.34652.1a

Iyer, S., Ferrario, C. and Chappell, M. (1998) Angiotensin-(1–7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. *Hypertension* **31**, 356–361, https://doi.org/10.1161/01.HYP.31.3.356

Keidar, S., Gamliel-Lazarovich, A., Kaplan, M., Pavlovitz, E., Hamouz, S., Hayek, T. et al. (2005) Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. *Cir. Res.* **97**, 946–953, https://doi.org/10.1136/crem.2004.027500.24964.7A

Sampaio, W.O., Henriques de Castro, C., Santos, R.A., Schiffрин, E.L. and Touyz, R.M. (2007) Angiotensin-(1–7) counterregulates angiotensin II signaling in human endothelial cells. *Hypertension* **50**, 1093–1098, https://doi.org/10.1161/HYPERTENSIONAHA.106.08448

Sampaio, W., Souza dos Santos, R., Faria-Silva, R., da Mata Machado, L., Schiffрин, E. and Touyz, R. (2007) Angiotensin-(1–7) through receptor mas mediates endothelial nitric oxide synthase activation via akt-dependent pathways. *Hypertension* **49**, 185–192, https://doi.org/10.1161/HYPERTENSIONAHA.106.08448

Sahara, M., Itokomi, M., Morita, T., Minami, Y., Nakajima, T., Hirata, Y. et al. (2013) Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation. *Cardiovasc. Res.* **101**, 236–246, https://doi.org/10.1093/cvr/cvt245

Song, B., Jin, H., Yu, X., Zhang, Z., Yu, H., Ye, J. et al. (2013) Angiotensin- converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and profilin-1/MAK signaling pathways. *Regul. Pept.* **185**, 44–51, https://doi.org/10.1016/j.regpep.2013.06.007

Zhang, C., Zhao, Y.X., Zhang, Y.H., Zhu, L., Deng, B.P., Zhou, Z.L. et al. (2010) Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 15886–15891, https://doi.org/10.1073/pnas.1001253107

Wang, J., Li, J., Cheng, C. and Liu, S. (2020) Angiotensin-converting enzyme 2 attenuates atherosclerosis and vascular inflammation on vascular smooth muscle cell phenotype transition. *Cell Tissue Res.* **382**, 599–618, https://doi.org/10.1007/s00441-020-03259-w

Rentzos, B., Todiras, M., Iliouss, R., Popova, E., Campos, L.A., Oliveira, M.L. et al. (2008) Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. *Hypertension* **52**, 967–973, https://doi.org/10.1161/HYPERTENSIONAHA.108.114322

Díez-Freire, C., Vázquez, J., Correa de Adjoumaun, M.F., Ferrari, M.F., Yuan, L., Silver, X. et al. (2006) ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. *Physiol. Genomics* **27**, 12–19, https://doi.org/10.1152/physiolgenomics.00312.2005

Hernández Prada, J., Ferreira, A., Katovich, M., Shenoy, V., Qi, Y., Santos, R. et al. (2008) Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. *Hypertension* **51**, 1312–1317, https://doi.org/10.1161/HYPERTENSIONAHA.107.108944

Lo, J., Patel, V.B., Wang, Z., Lewasseur, J., Kaufman, S., Penninger, J.M. et al. (2013) Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats. *Exp. Physiol.* **98**, 109–122, https://doi.org/10.1113/expphysiol.2012.067165

Rabelo, L., Todiras, M., Nunes-Souza, V., Gadri, F., Szijártó, I., Gollasch, M. et al. (2014) Genetic deletion of ace2 induces vascular dysfunction in c57b/6 mice: role of nitric oxide imbalance and oxidative stress. *Plos One* **11**, e015025, https://doi.org/10.1371/journal.pone.0150255

Thomas, M., Pickering, R., Tsorotes, D., Kolka, A., Sheehy, K., Bernardi, S. et al. (2014) Genetic Ace2 Deficiency Accentsuates Vascular inflammation and Atherosclerosis in the Apoe Knockout Mouse. *Circ. Res.* **107**, 888–897, https://doi.org/10.1161/CIRCRESAHA.110.219279

Zhang, C., Zhao, Y.X., Zhang, Y.H., Zhu, L., Deng, B.P., Zhou, Z.L. et al. (2010) Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 15886–15891, https://doi.org/10.1073/pnas.1001253107

Shenoy, V., Kwon, K., Rathinasabapathy, A., Lin, S., Jin, G., Song, C. et al. (2014) Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1–7) bioencapsulated in plant cells attenuates pulmonary hypertension. *Hypertension* **64**, 1248–1259, https://doi.org/10.1161/HYPERTENSIONAHA.114.03871

Ferreira, A., Shenoy, V., Yamazato, Y., Shirayama, S., Francis, J., Yuan, L. et al. (2009) Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. *Am. J. Respir. Crit. Care Med.* **179**, 1048–1054, https://doi.org/10.1164/rccm.200811-1678OC

Patel, V.B., Zhong, J.C., Fan, D., Basu, R., Morton, J.S., Parajuli, N. et al. (2014) Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodelling. *Hypertension* **64**, 157–164, https://doi.org/10.1161/HYPERTENSIONAHA.113.03388

Thatcher, S.E., Zhang, X., Howatt, D.A., Yiamkiousris, F., Gurlay, S.B., Ennis, T. et al. (2014) Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. *Arterioscler. Thromb. Vasc. Biol.* **34**, 2617–2623, https://doi.org/10.1161/ATVBAHA.113.304613

Chirinos, J.A., Cohen, J.B., Zhao, L., Harff, T., Szwietz, N., Fang, J. et al. (2020) Clinical and proteomic correlates of plasma ACE2 (angiotensin-converting enzyme 2) in human heart failure. *Hypertension* **76**, 1526–1536, https://doi.org/10.1161/HYPERTENSIONAHA.120.15829

Hemnes, A., Rathinasabapathy, A., Austin, E.A., Brittain, E.L., Carrier, E.J., Chen, X. et al. (2018) A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. *Eur. Respir. J.* **51**, 1702638, https://doi.org/10.1183/13993003.02638-2017

Khan, A., Benthin, C., Zeno, B., Albertson, T., Boyd, J., Christie, J. et al. (2017) A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. *Crit. Care* **21**, 234, https://doi.org/10.1186/s13054-017-1823-x

Joshi, S., Wollenzien, H., Leclerc, E. and Jaraipau, Y. (2019) Hypoxic regulation of angiotensin-converting enzyme 2 and Mas receptor in human CD34+ cells. *J. Cell. Physiol.* **234**, 20420–20431, https://doi.org/10.1002/jcp.28643

Joshi, S., Mahoney, S., Jahan, J., Plts, L., Hackney, K. and Jarajapu, Y. (2020) Blood flow restriction exercise stimulates mobilization of hematopoietic stem/progenitor cells and increases the circulating ACE2 levels in healthy adults. *J. Appl. Physiol.* **128**, 1423–1431, https://doi.org/10.1152/japplphysiol.00109.2020
125 Clark, M., Diz, D. and Tallant, E. (2001) Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. *Hypertension* **37**, 1141–1146, https://doi.org/10.1161/01.HYP.37.11.1141

126 Li, N., Cai, R., Niu, Y., Shen, B., Xu, J. and Cheng, Y. (2012) Inhibition of angiotensin II-induced contraction of human airway smooth muscle cells by angiotensin-(1-7) via downregulation of the RhoA/ROCK2 signaling pathway. *Int. J. Mol. Med.* **30**, 811–818, https://doi.org/10.3892/ijmm.2012.1080

127 Zhang, F., Li, S., Song, J., Liu, J., Cui, Y. and Chen, H. (2017) Angiotensin-(1-7) regulates angiotensin II-induced matrix metalloproteinase-8 in vascular smooth muscle cells. *Atherosclerosis* **261**, 90–98, https://doi.org/10.1016/j.atherosclerosis.2017.02.012

128 Bihl, J., Zhang, C., Zhao, Y., Xiao, X., Ma, X., Chen, Y. et al. (2015) Angiotensin-(1-7) counteracts the effects of Ang II on vascular smooth muscle cells, vascular remodelling and hemorrhagic stroke: Role of the NFB inflammatory pathway. *Vasc. Pharmacol.* **73**, 115–123, https://doi.org/10.1016/j.vph.2015.08.007

129 Tan, J., Xia, J., He, H., Chen, F., Fan, J., Ou, S. et al. (2020) Influence of angiotensin-(1-7) on cell activation in rat renal interstitial fibroblasts induced by aldosterone. *Xi. Bao. Yuxi. Zhi.* **28**, 808–810

130 Tao, X., Fan, J., Kao, G., Zhang, X., Su, L., Yin, Y. et al. (2014) Angiotensin-(1-7) attenuates angiotensin II-induced signaling associated with activation of a tyrosine phosphatase in Sprague-Dawley rats cardiac fibroblasts. *Biol. Cell* **106**, 182–192, https://doi.org/10.1111/boc.201400015

131 Chen, Y., Fan, J., Cao, L., Han, T., Zeng, M., Xu, Y. et al. (2019) Unique mechanistic insights into the beneficial effects of angiotensin-(1-7) on the prevention of cardiac fibrosis: A metabolomic analysis of preclinical cardiac fibrosis. *Exp. Cell Res.* **378**, 158–170, https://doi.org/10.1016/j.yexcr.2019.03.006

132 Montezano, A.C., Nguyen Dinh Cat, A., Rios, F.J. and Touyz, R.M. (2014) Angiotensin II and vascular injury. *Curr. Hypertens. Rep.* **16**, 431, https://doi.org/10.1007/s11906-014-0431-2

133 Zhang, Z., Chen, L., Zhong, J., Gao, P. and Ouïdit, G. (2014) ACE2/Ang-(1-7) signaling and vascular remodelling. *Sci. China Life Sci.* **57**, 802–808, https://doi.org/10.1007/s11427-014-4693-3

134 Fraga-Silva, R., Costa-Fraga, F., Murça, T., Moraes, P., Martins Lima, A., Lautner, R. et al. (2013) Angiotensin-Converting Enzyme 2 activation improves endothelial function. *Hypertension* **61**, 1233–1238, https://doi.org/10.1161/HYPERTENSIONAHA.111.06627

135 Xu, P., Costa-Goncalves, A., Todiras, M., Rabelo, L., Sampaio, W., Moura, M. et al. (2008) Endothelial dysfunction and elevated blood pressure in mas gene-deleted mice. *Hypertension* **57**, 574–580, https://doi.org/10.1161/HYPERTENSIONAHA.107.102764

136 Santos, R., Castro, C., Gava, E., Pinheiro, S., Almeida, A., de Paula, R. et al. (2006) Impairment of in vitro and in vivo heart function in mas-deficient mice. *Hypertension* **47**, 996–1002, https://doi.org/10.1161/01.HYP.0000215289.51180.5c

137 Simões e Silva, A., Silveira, K., Ferreira, A. and Teixeira, M. (2013) ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. *Br. J. Pharmacol.* **169**, 477–492, https://doi.org/10.1111/bjph.12159

138 Villalobos, L., San Hipólito-Luengo, Á., Ramos-González, M., Cercas, E., Vallejo, S., Romero, A. et al. (2016) The Angiotensin-(1-7)/Mas axis counteracts angiotensin II-dependent and-independent pro-inflammatory signaling in human vascular smooth muscle cells. *Front. Pharmacol.* **7**, 482, https://doi.org/10.3389/fphar.2016.00482

139 Wang, L., Hu, X., Zhang, W. and Tian, F. (2012) Angiotensin-(1-7) ameliorates angiotensin II-induced inflammation by inhibiting LOX-1 expression. *Inflamm. Res.* **62**, 219–228, https://doi.org/10.1007/s00011-012-0571-2

140 Zhang, Y., Zhang, Y., Dong, X., Hao, Q., Zhou, X., Tu, G. et al. (2015) ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response. *Inflamm. Res.* **64**, 253–260, https://doi.org/10.1007/s00011-015-0805-1

141 Nguyen Dinh Cat, A., Montezano, A., Burger, D. and Touyz, R. (2013) Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. *Antioxid. Redox Signal.* **19**, 1110–1120, https://doi.org/10.1089/ars.2012.4641

142 Zhang, Y., Liu, J., Luo, J., Tian, X., Cheang, W., Xu, J. et al. (2015) Upregulation of Angiotensin-(1-7)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes. *Antioxid. Redox Signal.* **23**, 880–892, https://doi.org/10.1089/ars.2014.6070

143 Lin, L., Liu, X., Xu, J., Weng, L., Ren, J., Ge, J. et al. (2015) Mas receptor mediates cardioprotection of angiotensin-(1-7) against Angiotensin II-induced cardiomyocyte autophagy and cardiac remodelling through inhibition of oxidative stress. *J. Cell. Mol. Med.* **20**, 48–57, https://doi.org/10.1111/jcmm.12687

144 Wang, J., Chen, S. and Bihl, J. (2020) Exosome-mediated transfer of ACE2 (angiotensin-converting enzyme 2) from endothelial progenitor cells promotes survival and function of endothelial cell. *Oxid. Med. Cell. Longev.* **2020**, 1–11

145 Arroja, M., Reid, E., Roy, L., Vallatos, A., Holmes, W., Nicklin, S. et al. (2019) Assessing the effects of Ang-(1-7) therapy following transient middle cerebral artery occlusion. *Sci. Rep.* **9**, 3154, https://doi.org/10.1038/s41598-019-39102-8

146 Benter, I., Yousif, M., Dhaunsi, G., Kaur, J., Chappell, M. and Diz, D. (2007) Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. *Am. J. Nephrol.* **28**, 25–33, https://doi.org/10.1159/000108758

147 Ma, Y., Huang, H., Jiang, J., Wu, L., Lin, C., Tang, A. et al. (2016) AVE 0991 attenuates cardiac hypertrophy through reducing oxidative stress. *Biochem. Biophys. Res. Commun.* **474**, 624–625, https://doi.org/10.1016/j.bbrc.2015.09.050

148 Rathinasabapathy, A., Bryant, A., Suzuki, T., Moore, C., Shay, S., Gladson, S. et al. (2018) rHAACE2 therapy modifies bleomycin-induced pulmonary hypertension via rescue of vascular remodeling. *Front. Physiol.* **9**, 271, https://doi.org/10.3389/fphys.2018.00271

149 Guo, L., Yin, A., Zhang, Q., Zhong, T., O’Rourke, S. and Sun, C. (2017) Angiotensin-(1-7) attenuates angiotensin II-induced cardiac hypertrophy via a Sirt3-dependent mechanism. *Am. J. Physiol. Heart Circ. Physiol.* **312**, H898–H911, https://doi.org/10.1152/ajpheart.00768.2016

150 Fang, Y., Gao, F. and Liu, Z. (2019) Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hypoxic lung injury by regulating NF-κB and Nrf2 pathways. *QJM-Int. J. Med.* **112**, 914–924, https://doi.org/10.1093/qjmed/hcz206
177 Chen, Z., Li, M., Xu, J., Yu, J., Wang, X., Jiang, J. et al. (2005) Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus. J. Infect. Dis. 191, 755–760, https://doi.org/10.1086/427811

178 Ahmedaj-Shala, B., Vaja, R., Atanur, S., George, P., Kirkby, N. and Mitchell, J. (2020) Cardiorenal tissues express SARS-CoV-2 entry genes and basigin (BSG/CD147) increases with age in endothelial cells. J. Am. Coll. Cardiol. Basic Trans. Science. 5, 1111–1123

179 Soldatov, V., Kubekina, M., Sliaze, Y., Bruter, A. and Deykin, A. (2020) On the way from SARS-CoV-sensitive mice to murine COVID-19 model. Res. Results Pharmacol. 6, 1–7, https://doi.org/10.3897/rrespharmacology.6.53633

180 Winkler, E., Bailey, A., Kafai, N., Nair, S., McCune, B., Yu, J. et al. (2020) SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327–1335, https://doi.org/10.1038/s41590-020-0778-2

181 Nishiga, M., Wang, D.W., Han, Y., Lewis, D.B. and Wu, J.C. (2020) COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 17, 543–558, https://doi.org/10.1038/s41569-020-0413-9

182 Guzik, T.J., Mohiddin, S.A., Dimarco, A., Patel, V., Savvatis, K., Marelli-Berg, F. et al. (2020) COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 116, 1666–1687, https://doi.org/10.1093/cvr/cvaa106

183 Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J., Xie, J. et al. (2020) Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ. Res. 126, 1671–1681, https://doi.org/10.1161/CIRCRESAHA.120.317134

184 Sardu, C., Gambardella, J., Morelli, M., Wang, X., Marfella, R. and Santulli, G. (2020) Hypertension, thrombosis, kidney Failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J. Clin. Med. 9, 1417, https://doi.org/10.3390/jcm9051417

185 Liu, P.P., Blet, A., Smyth, D. and Li, H. (2020) The science underlying COVID-19: Implications for the cardiovascular system. Circulation 142, 68–78, https://doi.org/10.1161/CIRCULATIONAHA.120.047549

186 Zheng, Y.Y., Ma, Y.T., Zhang, J.Y. and Xie, X. (2020) COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 17, 259–260, https://doi.org/10.1038/s41569-020-0360-5

187 Teuwen, L., Geldhof, V., Pasut, A. and Carmeliet, P. (2020) COVID-19: the vasculature unleashed. Nat. Rev. Immunol. 20, 389–391, https://doi.org/10.1038/s41577-020-0343-0

188 Varga, Z., Flammer, A., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. et al. (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417–1418, https://doi.org/10.1016/S0140-6736(20)30937-5

189 Oudit, G.Y., Kassiri, Z., Jiang, C., Liu, P.P., Poutanen, S.M., Penninger, J.M. et al. (2009) SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Invest. 39, 618–625, https://doi.org/10.1111/j.1365-2362.2009.02153.x

190 Scialo, F., Daniele, A., Amato, F., Pastore, L., Matera, M., Cazzola, M. et al. (2020) ACE2: The major cell entry receptor for SARS-CoV-2. Lung 198, 867–877, https://doi.org/10.1007/s00408-020-00408-4

191 Kaur, U., Acharya, K., Mondal, R., Singh, A., Saso, L., Chakrabarti, S. et al. (2020) Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2. Eur. J. Pharmacol. 887, 173545

192 Zhang, H., Penninger, J., Li, Y., Zhong, N. and Slutsky, A. (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 46, 586–590

193 Groß, S., Jahn, C., Cushman, S., Ba, C. and Thum, T. (2020) SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. J. Mol. Cell. Cardiol. 144, 47–53

194 Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R., Stahl, M. et al. (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905.e7–913.e7

195 Battle, D., Wysocki, J. and Satchell, K. (2020) Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin. Sci. (Lond.) 134, 543–545